ArticleInternational urology and nephrology2026
Efficacy of telitacicept on renal outcomes in patients with biopsy-proven lupus nephritis: a 12-month follow-up pilot study.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy of telitacicept in patients with biopsy-proven lupus nephritis.
methodsTwenty-one patients diagnosed with lupus nephritis by taking the renal biopsy were enrolled in this study and received telitacicept treatment for at least 6 months. The laboratory test and renal remission rate were assessed during the follow-up period.
resultsAll patients were followed for at least 12 months. At the 12-month follow-up, patients with Class II, III, or V LN all had achieved complete or at least partial remission, whereas some patients with Class III + V, IV, or IV + V LN had not achieved remission. However, with extended follow-up (median of 24 months), all patients ultimately achieved complete or partial remission by the end of the study. Significant improvements were observed at 3 months, including a decrease in the urinary protein to creatinine ratio (UPCR) and increases in serum albumin (ALB) and hemoglobin (Hb) levels. C3, C4 complement concentrations, and platelet (PLT) were markedly elevated at 1 month, while immunoglobulins (IgG, IgA, and IgM) decreased significantly and remained at low levels over the following 12 months. No severe adverse events were reported during the observation period. Compared with the noninitial-treatment group, patients initially treated with telitacicept had significantly lower baseline albumin, C3, and C4 levels, but subsequent follow-up revealed no statistically significant differences between the groups.
conclusionsTelitacicept is a promising treatment option for patients with LN. The study demonstrated favorable efficacy and safety in LN patients, regardless of whether they were undergoing initial therapy, had failed previous treatments, or had experienced disease relapse. Further randomized controlled trials are warranted to confirm this conclusion.
Indexed as
Identifiers
42498888What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.